Absci Corporation (ABSI)

NASDAQ: ABSI · IEX Real-Time Price · USD
5.66
+0.12 (2.17%)
Mar 28, 2024, 1:46 PM EDT - Market open

Company Description

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.

The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation
Absci logo
Country United States
Founded 2011
IPO Date Jul 22, 2021
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Sean McClain

Contact Details

Address:
18105 Se Mill Plain Blvd
Vancouver, Washington 98683
United States
Phone (360) 949-1041
Website absci.com

Stock Details

Ticker Symbol ABSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001672688
CUSIP Number 00091E109
ISIN Number US00091E1091
Employer ID 85-3383487
SIC Code 8731

Key Executives

Name Position
Sean McClain Founder, Chief Executive Officer, President and Director
Dr. Zachariah Jonasson Ph.D. Chief Business Officer and Chief Financial Officer
Dr. Andreas Busch Ph.D. Chief Innovation Officer and Member of Scientific Advisory Board
Alexander Khan CPA Vice President of Finance and Head of Investor Relations
Jack Gold Chief Marketing Officer
Karin Wierinck Chief People Officer
Melissa Patterson Ph.D. Chief of Staff
Jens Plassmeier Ph.D. Senior Vice President of Biologics Discovery Technology
Wen Sha Chief of Staff
Dr. Christine Lemke D.V.M., M.B.A., Ph.D. Senior Vice President of Portfolio and Growth Strategy

Latest SEC Filings

Date Type Title
Mar 21, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Mar 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 28, 2024 8-K Current Report
Feb 28, 2024 424B5 Filing
Feb 27, 2024 8-K Current Report
Feb 27, 2024 424B5 Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals